NEWS RELEASES

Date Title
Jan 9, 2019
Summary ToggleINSYS Therapeutics Announces Results of Dose-Finding PK Study for Epinephrine Nasal Spray for Treatment of Anaphylaxis Company’s Proprietary Formulation Continues to Show Promise as Potential Alternative to Intramuscular Injection PHOENIX , Jan. 09, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and Printer Friendly Version
Jan 3, 2019
Summary ToggleINSYS Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference PHOENIX , Jan. 03, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari , president and chief executive officer, and Andy Long , chief Printer Friendly Version